T3	eligibility 515 649	Postmenopausal women with a stage 0 through III breast cancer who received an AI and had treatment-associated musculoskeletal symptoms
T10	intervention-participants 1251 1253	23
T11	control-participants 1281 1283	24
T12	outcome 1420 1426	scores
T13	outcome 1481 1485	CESD
T14	outcome 1498 1516	hot flash severity
T15	outcome 1529 1548	hot flash frequency
T17	outcome 1587 1612	NSABP menopausal symptoms
T18	outcome 1676 1683	EuroQol
T20	outcome 1721 1746	NSABP menopausal symptoms
T21	ethinicity 1792 1808	African American
T22	ethinicity 1871 1891	non-African American
T4	intervention 147 158	acupuncture
T8	condition 171 223	aromatase inhibitor-induced musculoskeletal symptoms
T1	control 1300 1302	SA
T2	outcome 1565 1570	HFRDI
T16	outcome 1922 1940	hot flash severity
T19	outcome 1956 1965	frequency
